Research programme: hepatocyte growth factor kringle fragments - EntreMedAlternative Names: K2-3; NK1-3
Latest Information Update: 13 Jul 2007
At a glance
- Originator EntreMed
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 13 Jul 2007 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 03 Sep 2003 This project is available for licensing (http://www.entremed.com)
- 03 Apr 2001 Preclinical development for Cancer in USA (unspecified route)